Indication

Eosinophilic granulomatosis with polyangiitis

Eosinophilic granulomatosis with polyangiitis, formerly known as Churg-Strauss syndrome, is a rare systemic necrotizing vasculitis classified among the antineutrophil cytoplasmic antibody-associated vasculitides. Read more about Eosinophilic granulomatosis with polyangiitis

3 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Eosinophilic granulomatosis with polyangiitis therapies.

Showing 1–3 of 3 drugs

NUCALA (mepolizumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 5 ANTAGONIST·HYPEREOSINOPHILIC SYNDROME·+4
GSK

FASENRA (benralizumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 5 ANTAGONIST·HYPEREOSINOPHILIC SYNDROME·+2
AstraZeneca Pharmaceuticals

FASENRA PEN (benralizumab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 5 ANTAGONIST·HYPEREOSINOPHILIC SYNDROME·+2
AstraZeneca Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Eosinophilic granulomatosis with polyangiitis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Eosinophilic granulomatosis with polyangiitis.

Eosinophilic granulomatosis with polyangiitis, formerly known as Churg-Strauss syndrome, is a rare systemic necrotizing vasculitis classified among the antineutrophil cytoplasmic antibody-associated vasculitides.

It predominantly targets small- to medium-sized blood vessels and most frequently affects the respiratory tract, peripheral nerves, skin, cardiovascular system, and gastrointestinal tract.

Hallmark pathophysiologic and clinical features include severe adult-onset asthma, chronic rhinosinusitis, marked peripheral blood and tissue hypereosinophilia, and extravascular necrotizing granulomas.

Systemic vasculitic complications commonly manifest as mononeuritis multiplex, pulmonary infiltrates, or eosinophilic myocarditis.

Personalize your experience

Follow Eosinophilic granulomatosis with polyangiitis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it